buparvaquone has been researched along with silicon in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lehto, VP; Mondal, S; Näkki, S; Närvänen, A; Nissinen, T; Rantanen, J; Riikonen, J; Thapa, R | 1 |
1 other study(ies) available for buparvaquone and silicon
| Article | Year |
|---|---|
Biogenic nanoporous silicon carrier improves the efficacy of buparvaquone against resistant visceral leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Drug Carriers; Female; Hordeum; Injections, Intraperitoneal; Leishmania donovani; Leishmaniasis, Visceral; Macrophages; Mice, Inbred BALB C; Nanoparticles; Naphthoquinones; Silicon | 2021 |